Introduction
T helper 2 (Th2) cytokines in inflamed tissues lead to eosinophilia, high levels of serum IgE and mast cell activation, all of which contribute to the pathogenesis of allergic diseases. 2 CCR4 is also expressed by immune suppressive regulatory T cells, 3, 4 and a minor subset of Th17 cells. 5, 6 Hence CCR4
antagonists represent a novel therapeutic intervention in diseases where CCR4 is involved, such as asthma, 7 lung disease, 3 atopic dermatitis, 8 allergic bronchopulmonary aspergillosis, Indazole 3 was the first candidate to be progressed to human studies; however, the compound suffered from low solubility and weak potency. 24 A back-up programme was therefore initiated to identify novel templates for lead optimisation studies. Our group has recently reported the identification of bicyclic heteroarenes as novel lead series of sulfonamide CCR4
antagonists. 25 Herein we disclose the identification of a second lead series, the benzimidazol-2-one sulfonamides. 
Chemistry
The initial hit came from a focused library of 2,3-dichlorobenzenesulfonamides designed on a knowledge driven approach. A virtual set of 1600 commercially available aryl or heteroaryl primary amines were enumerated as 2,3-dichlorobenzenesulfonamides, ensuring that the set contained novel starting points with desired physicochemical properties (MW <400, clogP <4, polar surface area <100, H-bond acceptor <10, H-bond donor <5). A library of about 100
sulfonamides was synthesised and assayed in the GTPS assay. Hits were required to have a pIC 50 greater than that of the starting point of the indazole series (7) in the GTPS assay, and also better physicochemical properties than 7 (clogP <3.5, chrom logD 7.4 <5.3 and CLND solubility >116 g/mL). A subset of 14 of the most active compounds was tested for chemical stability in simulated gastric fluid and for photo-stability, and the unstable compounds were removed from the set to leave 10 hits. We have already reported for our indazole series, 22 and more recently for the bicyclic heteroarene series 25 that introduction of a hydrogen bond acceptor (HBA), suitably orientated to hydrogen-bond to the sulfonamide NH, increased the potency of these compounds approximately ten-fold. A methoxy group was then introduced to each of the 10 stable hits of our sulfonamide library to act as an HBA for the sulfonamide NH. Following screening of these methoxy analogues in the GTPS assay the benzimidazol-2-one sulfonamide 8 was identified as one of five hits suitable for further investigation. In this publication we disclose initial structure-activity relationships in this series, and the identification of a lead compound.
Figure 2 Initial indazole (7) and benzimidazolone (8) hits
Substitution with large benzyl groups was tolerated at the N1 position of the indazole series (for example compound 3). 21, 22 It was therefore important to find out whether substitution in the heterocyclic ring of the benzimidazolone scaffold was tolerated. Alkylation of 8 would produce three potential products, which would require separation and extensive characterisation. It was also known from previous studies 22 that alkylation of the sulfonamide nitrogen provided compounds devoid of any CCR4 activity. It was considered that treatment of 5-methoxy-6-nitro-benzimidazol-2-one 9 with one equivalent of electrophile in the presence of a base might produce one major product regioselectively as the acidity of the nitrogen atoms of the imidazolone ring was substantially different. The calculated pK a values (ACD software, version 11) for N1 (para to the nitro-group) was 10.9 and for N3
(para to methoxy-group) was 17.1. Hence, treatment of 9 with one equivalent of sodium hydride in DMF and one equivalent of electrophile was expected to give the N1-alkylation product as the major component. Indeed when iodomethane was used as the electrophile 10a
was obtained in 25% yield. The other mono-methyl product 11a was present in the reaction mixture only in trace amounts. The dimethyl product 12a was however also isolated in 14%
yield, which suggested that product 10a reacted further with iodomethane. The structure of the monomethyl regioisomer 10a was confirmed by NOE experiments. The HSQC spectrum confirmed the chemical shifts of the aromatic protons at the C4 (7.51 ppm) and C7-position (7.12 ppm). Irradiating the N-methyl protons (3.34 ppm) and O-methyl protons (3.94 ppm), resulted in both sets of protons giving an NOE to the proton at the C7-position (7.12 ppm), confirming the regiochemistry of the alkylation ( Figure 3 ). of the N1-position in relation to the MeO-and nitro-groups shown above could change depending on the substituent used, so throughout the report, the N1-position as shown above is used as an arbitrary number for ease of discussion.
Treatment of the sodium salt of 9 with 2-bromoacetamide gave a 9:1 mixture of 10b and 11b (Scheme 1). Similarly treatment of 9 with iso-propyl bromide or with 3-iodo-oxetane gave 10c and 10d respectively. The nitro-group of 10a-d, 11b and 12a,b was reduced with hydrogen over 10% palladium on carbon to give the corresponding aromatic amines, which were sulfonylated with 2,3-dichlorobenzenesulfonyl chloride in pyridine to give 13a-d, 14b
and 15a. The general method shown in Scheme 1 was unsuccessful for the preparation of the N3-methylated regioisomer 11a, so an alternative route to explore the N3-substitution using allyl protection was investigated (Scheme 2). The allyl group was chosen as a protecting group as it is stable to both acidic (nitric acid) and basic (sodium hydride) conditions, key requirements in the proposed synthetic route. Reaction of commercially available 2-fluoro-4-methoxy-1-nitrobenzene 16 with neat allylamine at room temperature afforded the nitroaniline 17 in 97% yield. The nitro group of 17 was reduced with iron and ammonium chloride to provide the phenylenediamine 18, which was then treated with CDI to give the methoxy benzimidazolone 19 in 45% yield. Nitration of 19 using fuming nitric acid and concentrated sulfuric acid or neat fuming nitric acid gave the undesired dinitro product 20.
Investigation of various other concentrations of nitric acid and sulfuric acid, identified 4M nitric acid as the best reagent for the preparation of the desired mono nitro product, 21 (23% yield). A small amount of the dinitro product, 20 and starting material were also present in the reaction mixture. Alkylation of 21 with methyl iodide was facile providing the methylated benzimidazolone 22 in excellent yield. Removal of the allyl group proved to be problematic. Attempts to use palladium catalysed conditions, involving the formation of π-allyl complex, 26 and those based on isomerisation of the allylamine double bond using RuCl 3 catalyst, followed by hydrolysis of the resulting enamine, were all found to be unsuccessful. The method of Nebra, 30 utilising commercially available ruthenium catalyst 24, and stoichiometric potassium periodate in water gave 23 in 40% yield. Finally reduction of 23 using catalytic hydrogenation over 10% Pd/C catalyst, followed by reaction with 2,3-dichlorobenzenesulfonyl chloride in pyridine gave the desired N3-methylated sulfonamide 14a in 7% yield. The N1-propyl analogue 13e was also obtained from this route by catalytic hydrogenation of 21 followed by sulfonylation.
A regioselective synthetic route for the preparation of N1-substituted benzimidazolones was developed and is outlined in Scheme 3. Reaction of 16 with a range of primary amines, such
as N,N-dimethylaminoethylamine, 2-aminopropane-1,3-diol, and 3-amino-1-BOC-azetidine in the presence of diisopropylamine (DIPEA) in DMF at room temperature gave 25 in 83-93% yields. Reduction of the nitro group of 25 with catalytic hydrogenation over 10% Pd/C in ethanol gave 26 in 70-97% yields. In the case of 25f the hydroxyls were protected as TBDMS ethers before proceeding to the hydrogenation step. The aromatic diamines 26 were then cyclised with carbonyl diimidazole (CDI) in THF at 50 °C to give 27 in 69-83% yield.
Benzimidazolones 27 were nitrated using 4M nitric acid to give the desired mono nitro products 10 in 33-53% yield, accompanied by a small amount of the di-nitration product. In the case of azetidine 10g the BOC protecting group was removed under the nitration conditions and it was re-installed using BOC 2 O in THF in the presence of NaHCO 3 . The nitro group of 10 was reduced by catalytic hydrogenation over 10% Pd/C to give 28 in high yields. The synthesis was completed by sulfonylation of 28 with 2,3-dichlorobenzenesulfonyl chloride in pyridine to give the desired sulfonamide 13 in moderate yields. In the case of BOC-13g the protecting group was removed using 4M HCl in dioxane.
Finally, 13g was converted to 13h using one equivalent of acetic anhydride in pyridine. Deady. 31 The latter was methylated with iodomethane in the presence of potassium carbonate in DMSO to give 31 in 80% yield. Nitration of 31 with conc. HNO 3 and conc. H 2 SO 4 at 65 °C gave 32 in 28% yield. The two bromine atoms of 32 were readily displaced by aqueous ammonia using microwave irradiation using a modification of the Barraclough procedure to give diamine 33 in 78% yield. 32 The latter was reacted with BOC 2 O to give the bis-protected diamine 34 in 66% yield, followed by reduction of the nitro group using iron in acetic acid to provide amine 35 in 78% yield. This compound was then heated in pyridine in a microwave oven at 100 °C to give the cyclised aza-benzimidazolone 36 in 74% yield. Cleavage of the BOC group with TFA gave 37 in 93%, and reaction of this product with 2,3-dichlorobenzenesulfonyl chloride in pyridine afforded the desired sulfonamide 38 in moderate yield (30%). 
Results and Discussion
All compounds in Table 1 were tested as human CCR4 antagonists in vitro. Antagonist potency was determined by a [ 35 S]-GTPS radioligand competition functional assay using recombinant CCR4-expressing CHO cell membranes adhered to WGA-coated Leadseeker SPA beads in assay buffer at pH 7.4. 33 Another assay using human whole blood was used as a secondary screen to determine potency against the native receptor for the more potent compounds in the primary assay. 22 The assay quantified cytoskeletal reorganization (formation of filamentous (F-) actin) which occurs in a variety of cells in response to chemoattractants and is a prelude to chemotaxis. This was achieved by staining the F-actin with a fluorescent derivative of phalloidin, which binds with high affinity and specificity to the interface between actin monomers in F-actin. The response was measured as an increase in the fluorescence intensity of the target cell population in a flow cytometer and was expressed as a pA 2 Compounds 2 and 4 were used as standards in the GTPγS assay and included in Table 1 . The data generated for 7, the initial lead that lead to indazole candidate 3, are also included in Table 1 for comparison. The initial benzimidazolone hit 8 was slightly more potent than 7
(pIC 50 = 6.5), with higher LE (0.38), and lower lipophilicity (chrom logD 7.4 3.2), but with lower solubility. Substitution at the benzimidazolone N1-position with methyl or acetamide groups (13a and 13b) was tolerated, however, substitution at N3 (14a and 14b) reduced potency by 100-fold. The N1,N3-dimethyl analogue 15a was ten-fold less potent than 13a.
It was encouraging to observe that removal of a hydrogen bond donor (HBD) from the benzimidazolone core was tolerated. In general reducing the number of HBD's in a compound increases permeability, although the solubility might be reduced. 34, 35 The N1-position was further explored with small lipophilic, polar and weakly basic groups in an attempt to improve the potency, solubility and physicochemical property of the series.
Replacing the methyl group at the N1-position for n-propyl group (13c) reduced both the potency and the solubility. Replacing methyl for isopropyl group (13d) caused a marginal increase in potency, accompanied by increased lipophilicity (clogP = 4.4). The two basic analogues 13e and 13g, the diol 13f, and the amide 13h were made to increase the solubility of the molecules. However, despite the observed increases in solubilities, their potencies were lower than the previous compounds. The oxetane group was utilised to improve the solubility and permeability of other scaffolds. 36 The oxetanyl analogue 13i was equipotent to the methyl analogue 13a, and it was also less lipophilic, however, its solubility remained low.
Furthermore, 13i was found to be unstable, and no further substitutions were investigated.
It was noted that all three sulfonamide CCR4 antagonist candidates 1, 2 and 3 contain a nitrogen heterocycle (pyrazine or indazole), and that the nitrogen atom of the heterocyclic ring was ortho-to the sulfonamide nitrogen. Similarly, a 10-fold increase of potency was observed in our lead generation work for a back-up series to compound 3 after the introduction of an ortho-nitrogen atom to phenylpyrazole to form pyridylpyrazole sulfonamides. Furthermore, the introduction of nitrogen into the phenyl ring of the benzimidazolone 8 was expected to enhance its solubility and physicochemical properties.
This strategy was more successful than the removal of an HBD, or the introduction of solubilising groups. Thus, replacement of the C4-methine with nitrogen (compound 38)
resulted in more than a log unit increase in GTPγS potency (pIC 50 = 7.6), and a substantial increase in ligand efficiency (LE = 0.43). Furthermore, its lipophilicity was decreased (clogP = 3.6 and chrom logD 7.4 = 2.4), and its solubility increased by more than three-fold compared to 8. Introducing nitrogen at C7 (compound 43) also increased potency in the GTPγS assay, but only by half a log unit while it increased its LE to 0.40. The lipophilicity was also decreased, but not by as much as in the case of 38. Its solubility was increased by three-fold to 126 g/mL. Introducing two nitrogen atoms to the benzimidazolone phenyl ring provided pyrazine 49, which increased its pIC 50 to 7.3, LE to 0.41, and its solubility by three-fold higher than 8.
Human whole blood F-actin polymerisation assay and physicochemical data were obtained for the most potent compounds of the benzimidazolone series, and the results are also summarised in Table 1 . The parent benzimidazolone 8 was weakly active in this assay and had a pA 2 value of 5.3. Although the N1 isopropyl analogue 13d was slightly more potent than 8 in the GTPS assay, it was inactive in the whole blood assay (pA 2 <5). The three azabenzimidazolone analogues 38, 43 and 49 were all found to be active, with compound 38
exhibiting whole blood activity similar to that of the indazole candidate 3. The whole blood activity data for 38 (pA 2 = 6.1) is very encouraging as its molecular weight is lower than 3,
(389 vs 549), it displays a higher LE of 0.43 (cf. 3 LE = 0.29), and it is more soluble than 3.
It is also much less lipophilic than 3 (chrom logD 7.4 = 2.4 vs 4.3). In addition, the azabenzimidazolones 38, 43 and 49 have human serum albumin binding around 93%, which is substantially lower than 3 (96.5%). This translates to twice the unbound fraction of 38 available for distribution to the desired tissues.
Conclusion
The aim of this work was to obtain human CCR4 antagonists which were more potent than the starting point of our indazole candidate, had better physicochemical properties (clogP <3.5, chrom logD 7.4 <5.3 and CLND solubility >116 g/mL), and were stable to acid and light. A novel series of 2,3-dichlorophenylsulfonamide derivatives of benzimidazol-2-one were synthesised and examined as CCR4 antagonists. Substitution with small alkyl groups at N1 was tolerated; however, substitution at N3 or di-substitution at both N1 and N3 was not tolerated. Introduction of nitrogen in the benzimidazolone phenyl ring increased potency, ligand efficiency and solubility, whilst reducing the lipophilicity and human serum albumin binding. Aza-benzimidazolone 38 was equipotent with our indazole candidate 3 in the whole blood assay with a pA 2 of 6.1, making 38 a very attractive starting point for lead optimisation. The CLND solubility of 38 was 152 g/mL, which is on the lower limit for an oral candidate. Introduction of small water-solubilising groups, either as substituents at N1, or in the aromatic ring of the core would be expected to overcome this problem. Further investigation of this template will not be undertaken, however, due to closure of the project.
Experimental Section
Organic solutions were dried over anhydrous Na 2 The purity of all compounds screened in the biological assays was examined by LCMS analysis and was found to be  95%, unless otherwise specified. All animal studies were ethically reviewed and carried out in accordance with Animals (Scientific Procedures) Act 1986 and the GSK Policy on the Care, Welfare and Treatment of Laboratory Animals. The human biological samples were sourced ethically and their research use was in accord with the terms of the informed consents.
2,3-Dichloro-N-(6-methoxy-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)benzenesulfonamide (8)
A solution of 5-amino-6-methoxy- 
5-Methoxy-6-nitro-1H-benzo[d]imidazol-2(3H)-one (9)
A solution of 17.5% fuming nitric acid (12.5 mL, 48.9 mmol) was slowly added to 5- 
6-Methoxy-1-methyl-5-nitro-1H-benzo[d]imidazol-2(3H)-one (10a) and 5-methoxy-

1,3-dimethyl-6-nitro-1H-benzo[d]imidazol-2(3H)-one (12a)
Sodium hydride (15 mg of a 60% w/w dispersion in mineral oil, 0.38 mmol) was added to a stirring solution of 9 (75 mg, 0.36 mmol) in anhydrous DMF (1 mL) at 0 ºC. Methyl iodide (0.02 mL, 0.36 mmol) was added and the reaction mixture was stirred at ambient temperature for 4 h. The reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL). The organic layer was separated, washed with water (10 mL), brine (10 mL), dried and evaporated under reduced pressure. The residue was taken up in DMSO (2 mL) and purified by MDAP. The appropriate fractions were combined and the solvent was evaporated under reduced pressure to give 10a (20 according to the procedure described for the preparation of 13a. 
2-(5-
(
1-Isopropyl-5-methoxy-6-nitro-1H-benzo[d]imidazol-2(3H)-one (10c)
From 9 according to the procedure described for the preparation of 10a: 
N1-allyl-5-methoxybenzene-1,2-diamine (18)
Iron powder (3.5 g, 325 mesh, 62 mmol) was added to a solution of 17 (2.6 g, 12 mmol) in ethanol (70 mL) and water (35 mL). Ammonium chloride (1.8 g, 33 mmol) was added in one portion, and the reaction mixture was refluxed for 24 h. Ethanol was removed under reduced pressure, and the residue was partitioned between ethyl acetate (500 mL) and saturated aqueous sodium bicarbonate solution (500 mL). The organic layer was separated and the aqueous layer was extracted with more ethyl acetate (2 × 300 mL). The combined organic 
1-Allyl-6-methoxy-1H-benzo[d]imidazol-2(3H)-one (19)
CDI (110 
1-Allyl-6-methoxy-5-nitro-1H-benzo[d]imidazol-2(3H)-one (21)
Nitric acid (4M, 66.5 mL) was cooled to 0 ºC and added slowly to 19 (1.9 g, 9.3 mmol). The reaction mixture was stirred for 1 h at 0 ºC and then allowed to warm to ambient temperature and stirred for 3 h. Some of the starting material dropped out of solution and formed a gum.
Glacial acetic acid (5 mL) was added and the reaction was stirred at ambient temperature for 2 h. The reaction mixture was poured onto 30 mL of iced-water and was neutralised with saturated sodium bicarbonate solution. The product was extracted with ethyl acetate (2 × 300 mL), and the combined organic extracts were washed with brine (100 mL), dried and evaporated under reduced pressure. The residue was purified by chromatography on silica (100 g cartridge) eluting with a gradient of 0-100% ethyl acetate-cyclohexane over 60 min. 
1-Allyl-6-methoxy-3-methyl-5-nitro-1H-benzo[d]imidazol-2(3H)-one (22)
Sodium hydride (18 mg of a 60% w/w dispersion in mineral oil, 0.46 mmol) was added to a stirring solution of 21 (105 mg, 0.42 mmol) in anhydrous DMF (1 mL) at 0 ºC. The mixture was stirred for 20 min, then methyl iodide (0.03 mL, 0.46 mmol) was added and the reaction mixture was allowed to warm to ambient temperature over 2 h. The reaction mixture was quenched with water (20 mL) and the product was extracted with ethyl acetate (3 × 20 mL).
The combined organic extracts were washed with water (20 mL), brine (2 × 20 mL), dried 
5-Methoxy-1-methyl-6-nitro-1H-benzo[d]imidazol-2(3H)-one (11a)
Compound 22 
2,3-Dichloro-N-(6-methoxy-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)benzenesulfonamide (14a)
From 11a according to the procedure described for the preparation of 13a afforded 14a (4 mg, 22%) as a white solid 
2-((5-Methoxy-2-nitrophenyl)amino)propane-1,3-diol (25g)
Was similarly prepared to give 25g (1. 
tert-Butyl 3-((5-methoxy-2-nitrophenyl)amino)azetidine-1-carboxylate (N-BOC25h)
Was prepared according to the procedure described for the preparation of 25f to give 25h 
N1-(2-(Dimethylamino)ethyl)-5-methoxybenzene-1,2-diamine (26f)
A solution of 25f (1.45 g, 6.06 mmol) in ethanol (100 mL) was hydrogenated over 10% palladium on carbon (0.65 g) for 18 h. The catalyst was removed by filtration through a pad of celite, washed with ethanol (150 mL) and concentrated under reduced pressure to give 26f 
1-(2-(Dimethylamino)ethyl)-6-methoxy-1H-benzo[d]imidazol-2(3H)-one (27f)
A mixture of 26f (1. 
1-(2-(Dimethylamino)ethyl)-6-methoxy-5-nitro-1H-benzo[d]imidazol-2(3H)-one (10f)
A suspension of 27f (1.26 g, 4.55 mmol) in nitric acid (4M, 60 mL) was stirred at ambient temperature for 22 h. The reaction mixture was poured over ice (50 mL), neutralised with solid sodium bicarbonate, and extracted with ethyl acetate (2 × 150 mL). The combined organic extracts were then washed with brine (100 mL), dried, and evaporated under reduced 
5-Amino-1-(2-(dimethylamino)ethyl)-6-methoxy-1H-benzo[d]imidazol-2(3H)-one (28f)
A solution of 10f (0.75 g, 2.4 mmol) in a mixture of ethanol (50 mL) and ethyl acetate (50 mL) was hydrogenated over 10% palladium on carbon (0.77g) for 18 h. 
tert-Butyl 3-(5-amino-6-methoxy-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)azetidine-1-carboxylate (N-BOC-28h)
From 
2,3-Dichloro-N-(1-(2-(dimethylamino)ethyl)-6-methoxy-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)benzenesulfonamide (13f)
From 28f (100 mg, 0.40 mmol) and 2,3-dichlorobenzenesulfonyl chloride (108 mg, 0.44 mmol) according to the procedure described for the preparation of 13a afforded 13f (67 mg, 36%) as a beige 
tert-Butyl
Di-tert-butyl (3-methoxy-5-nitropyridine-2,6-diyl)dicarbamate (34)
Di-tert-butyl dicarbonate (0.76 mL, 3.3 mmol) and K 2 CO 3 (560 mg, 4.10 mmol) were added to a solution of 33 (150 mg, 0.82 mmol) in DMF (4 mL). The reaction mixture was stirred at ambient temperature for 18 h, and then diluted with water (20 mL) and ethyl acetate (40 mL).
The organic layer was separated, washed with water (2 × 10 mL), brine (10 mL), dried, and concentrated under reduced pressure. 
5-Amino-6-methoxy-1H-imidazo[4,5-b]pyridin-2(3H)-one (37)
A mixture of 36 (50 mg, 0.18 mmol) and TFA (0.25 mL) was stirred at ambient temperature for 30 min. The mixture was concentrated under reduced pressure, the residue was dissolved in methanol and dichloromethane (1:1, 1 mL), and passed down an aminopropyl ionexchange cartridge (500 mg), eluting with methanol and dichloromethane (1:1, 10 mL 
5-Methoxy-1H-imidazo[4,5-b]pyridin-2(3H)-one (40)
CDI ( 
5-Methoxy-6-nitro-1H-imidazo[4,5-b]pyridin-2(3H)-one (41)
Compound 40 (266 mg, 1.61 mmol) was slowly added to trifluoroacetic anhydride (5.5 mL, (0.14 mL of a 70 wt% aqueous solution, 1.63 mmol) was added dropwise and the reaction was stirred at 0 ºC for a further 2 h. The reaction mixture was then slowly added to a solution of sodium metabisulfite (304 mg, 1.6 mmol) in water (14 mL) at 0 ºC, and the precipitate formed was collected by filtration to give 41 (160 mg, 47%) as a bright (g/mL) hWB
